Carol Pappas, MD
Neurology · St Petersburg, FLNPI 1659442101
Payments from drug & device makers
Across 348 payments — averaging $261.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$69K
- Neurocrine Biosciences, Inc.$13K
- Amneal Pharmaceuticals LLC$6K
- Biogen$641
- Acadia Pharmaceuticals Inc$300
- Sunovion Pharmaceuticals Inc.$297
- plus $2K from 30 others
Across 2 payments — averaging $11,686 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$23K
What the payments were for
- Consulting fees$7,3509%
- Speaking & faculty fees$59,09274%
- Travel & lodging$6,5498%
- Food & beverage$5,9257%
- Education$1,4412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 110 | $69,092 |
| Neurocrine Biosciences, Inc. | 31 | $12,629 |
| Amneal Pharmaceuticals LLC | 12 | $5,505 |
| Biogen | 34 | $641 |
| Acadia Pharmaceuticals Inc | 18 | $300 |
| Sunovion Pharmaceuticals Inc. | 20 | $297 |
| Lilly USA, LLC | 11 | $253 |
| Abbott | 4 | $239 |
| MDD US Operations, LLC | 22 | $235 |
| UCB, Inc. | 9 | $205 |
| Adamas Pharmaceuticals, Inc. | 7 | $150 |
| AstraZeneca(2 entities) | 5 | $118 |
| GE HealthCare | 7 | $115 |
| Argenx US, Inc. | 5 | $110 |
| Acorda Therapeutics, Inc | 7 | $107 |
| Kyowa Kirin, Inc. | 5 | $88 |
| Avion Pharmaceuticals | 4 | $84 |
| Mallinckrodt Hospital Products Inc. | 4 | $82 |
| Genentech USA, Inc. | 3 | $68 |
| Eisai Inc. | 2 | $61 |
| Pfizer | 3 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $49 |
| Grifols USA, LLC | 2 | $49 |
| Corium, LLC | 2 | $48 |
| Novartis | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| Microtransponder, Inc. | 1 | $37 |
| Sumitomo Pharma America, Inc. | 3 | $30 |
| EMD Serono, Inc. | 2 | $28 |
| Supernus Pharmaceuticals, Inc. | 2 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Viz.ai, Inc. | 1 | $23 |
| Arbor Pharmaceuticals, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Duopa$55,636
- ONGENTYS$16,578
- ONGENTYS 50MG CAPSULES 30$932
- INFINITY$150
- APTIOM$115
How this compares
$90,906 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 26 | $133,123 |
| OngentysOpicapone | 61 | $81,403 |
| Austedo XrDeutetrabenazine | 12 | $69,793 |
| NeuproRotigotine | 30 | $52,724 |
| EliquisApixaban | 40 | $33,509 |
| AptiomEslicarbazepine Acetate | 17 | $25,227 |
| Memantine Hcl ErMemantine Hcl | 112 | $17,895 |
| Rivastigmine | 40 | $9,408 |
| RytaryCarbidopa/Levodopa | 16 | $8,632 |
| Ropinirole ErRopinirole Hcl | 27 | $7,043 |
| Pregabalin | 128 | $5,914 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 16 | $5,015 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 155 | $4,595 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $2,858 |
| Donepezil Hcl | 72 | $2,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $300 | $133,12326 claims |
| Neurocrine Biosciences, Inc.Ongentys | $12,629 | $81,40361 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $49 | $69,79312 claims |
| UCB, Inc.Neupro | $205 | $52,72430 claims |
| PfizerEliquis | $58 | $33,50940 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $297 | $25,22717 claims |
| Amneal Pharmaceuticals LLCRytary | $5,505 | $8,63216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,434 neurology providers in Florida.
Other neurology in St Petersburg
- Mark GoldsteinAtlantis$36.1M
- Derrick RobertsonTampa$27.6M
- Beth SafirsteinHallandale Beach$25.7M
- Michael PfefferMiami$24.5M
- Mark BrodyDelray Beach$20.5M
- Paayal PatelWest Palm Beach$17.3M
- Wendy BondFort Myers$14.7M
- William HoneycuttMaitland$14.1M
- Julie SchwartzbardAventura$13.6M
- Rekha GandhiWinter Park$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.